BioCardia, Inc. (NASDAQ:BCDA) Short Interest Down 39.6% in January

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 50,400 shares, a decline of 39.6% from the December 31st total of 83,400 shares. Based on an average daily volume of 48,500 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.3% of the shares of the company are sold short.

BioCardia Price Performance

Shares of NASDAQ BCDA traded down $0.06 during mid-day trading on Thursday, hitting $2.32. The company had a trading volume of 23,617 shares, compared to its average volume of 46,464. BioCardia has a 12 month low of $1.63 and a 12 month high of $8.85. The stock has a market cap of $10.63 million, a price-to-earnings ratio of -0.55 and a beta of 1.26. The firm’s 50 day simple moving average is $2.20 and its two-hundred day simple moving average is $2.52.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of BioCardia in a research note on Wednesday, December 18th.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.